# AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

> **NCT05247684** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 90 (actual)

## Conditions studied

- Resectable Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AK112
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05247684
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-20
- **Primary completion:** 2025-08-18
- **Final completion:** 2026-12-31
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247684, "AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05247684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*